Selected
Healthy Cities

Fetosense

AI based fetal heart monitoring to reduce prematurity in low and middle income countries

Team Leader
Ameya Bondre
AI based fetal heart monitoring to reduce prematurity in low and middle income countries

The Problem

In many low- and middle-income countries (LMICs), over 80% of pregnant women receive antenatal care at primary facilities that lack fetal monitoring. Specialists are concentrated in urban hospitals, so fetal distress is often missed, causing delayed care, unnecessary referrals, and higher NICU admissions.

The Solution

Fetosense is a digital fetal monitoring platform developed by CareNX Innovations that enables specialist-quality fetal assessment at the primary healthcare level. It combines a portable cardiotocography (CTG) device with mobile connectivity, cloud-based telemonitoring, and an AI-powered decision-support system. Fetosense allows general physicians, nurses, and midwives to screen for fetal distress and remotely escalate high-risk cases to specialists. Designed for low-resource environments, the platform integrates into existing antenatal care and referral workflows, supports interoperability through FHIR-compatible APIs, and aligns with WHO digital health principles. Fetosense is being further enhanced through a UNICEF Venture Fund collaboration to develop an open-source AI module for broader global adoption.

Stats

Fetosense has screened over one million pregnant women using its portable fetal monitoring devices.

What is the name of your organization?
CareNX Innovations
What is the name of your solution?
Fetosense
Provide a one-line summary or tagline for your solution.
AI based fetal heart monitoring to reduce prematurity in low and middle income countries
In what city, town, or region is your solution team headquartered?
Mumbai
In what country is your solution team headquartered?
—
What type of organization is your solution team?
For-Profit
Film your elevator pitch.
—
What specific problem are you solving?
In many low- and middle-income countries (LMICs), over 80% of pregnant women receive antenatal care at primary facilities that lack fetal monitoring. Specialists are concentrated in urban hospitals, so fetal distress is often missed, causing delayed care, unnecessary referrals, and higher NICU admissions.
What is your solution?
Fetosense is a digital fetal monitoring platform developed by CareNX Innovations that enables specialist-quality fetal assessment at the primary healthcare level. It combines a portable cardiotocography (CTG) device with mobile connectivity, cloud-based telemonitoring, and an AI-powered decision-support system. Fetosense allows general physicians, nurses, and midwives to screen for fetal distress and remotely escalate high-risk cases to specialists. Designed for low-resource environments, the platform integrates into existing antenatal care and referral workflows, supports interoperability through FHIR-compatible APIs, and aligns with WHO digital health principles. Fetosense is being further enhanced through a UNICEF Venture Fund collaboration to develop an open-source AI module for broader global adoption.
Who does your solution serve, and in what ways will the solution impact their lives?
Fetosense serves pregnant women in low-resource and underserved settings, particularly those receiving care at primary health centers without regular access to specialists. By enabling early detection of fetal distress and timely referrals, the solution improves maternal and neonatal outcomes and reduces preventable complications. Fetosense also empowers frontline healthcare providers—general physicians, nurses, and midwives—by providing actionable clinical insights and remote specialist support. Health systems benefit through reduced unnecessary referrals, lower NICU admissions, and more efficient use of specialist resources. To date, Fetosense has screened over 500,000 pregnancies and reduced NICU admissions by more than 30%.

Organization Type:
For-Profit

Headquarters:
Mumbai, India

Stage:
Growth

Working In:
India

Solution Website:
www.carenx.com

Solution Team:
Ameya Bondre
Ameya Bondre
Head of Clinical Research and Development